NRIX

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.

Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 24.93 USD with a low forecast of 12.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nurix Therapeutics Inc revenue for the last quarter amounts to 7.89M USD, decreased -37.29 % YoY.

Nurix Therapeutics Inc. EPS for the last quarter amounts to -1.03 USD, increased 53.73 % YoY.

Nurix Therapeutics Inc (NRIX) has 286 emplpoyees as of December 15 2025.

Today NRIX has the market capitalization of 1.93B USD.